title: Mesalamine protects against colorectal cancer in inflammatory bowel disease.
abstract: BACKGROUND
  Individuals with inflammatory bowel disease (IBD) are at increased risk of developing colorectal cancer (CRC) compared with the general population. Previous studies show this risk is strongly associated with dysplasia, extent of disease, duration of disease, and degree of inflammation, while chemoprevention of CRC has less support.
  
  
  OBJECTIVE
  Evaluate factors influencing risk of colorectal cancer development in inflammatory bowel disease patients.
  
  
  METHODS
  IBD patients with CRC were matched to controls by IBD type, age at diagnosis, sex, race, extent of disease, and disease duration. We compared body mass index, family history of IBD, family history of CRC, tobacco use, and cumulative and daily use of aminosalicylates, immunomodulators, folic acid, steroids, and nonsteroidal anti-inflammatory drugs. Statistical analysis was performed with logistic regression and receiver operating characteristic (ROC) curves.
  
  
  RESULTS
  Of 1,594 IBD patients, 30 CRC patients were identified. Of these, 18 CRC patients were matched to 30 controls. More control patients used a cumulative aminosalicylate dose of >or=4,500 g (46.6% versus 5.6%; P = 0.047), folic acid (40.0% versus 16.7%; P = 0.002), cumulative folic acid dose of >or=1,400 mg (30.0% versus 11.1%; P = 0.014), and average daily folic acid dose of >or=1 mg (30.0% versus 16.7%; P = 0.002) compared with CRC patients. Multivariate analysis showed that a cumulative aminosalicylate dose of >or=4,500 g reduced the risk of CRC by 97.6% (P = 0.047). Folic acid reduced CRC risk by 89% (P = 0.002).
  
  
  CONCLUSIONS
  Aminosalicylate and folic acid use may decrease the risk of CRC among IBD patients.
authors.affiliation: Department of Internal Medicine, Division of Gastroenterology, Henry Ford Health System, Henry Ford Hospital, Detroit, MI 48202, USA. jtang2@hfhs.org
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Tang
authors.forename: Omar
authors.initials: O
authors.lastname: Sharif
authors.forename: Chetan
authors.initials: C
authors.lastname: Pai
authors.forename: Ann L
authors.initials: AL
authors.lastname: Silverman
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D015179:Colorectal Neoplasms / Q000209:etiology / Q000517:prevention & control*; D018450:Disease Progression; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000188:drug therapy*; D016015:Logistic Models; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use*; D008875:Middle Aged; D016017:Odds Ratio; D012372:ROC Curve; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D005765:Gastrointestinal Agents; D019804:Mesalamine; D005492:Folic Acid
references.citation: Gastroenterology. 2004 Feb;126(2):451-9
references.pmid: 14762782
references.citation: World J Gastroenterol. 2006 Oct 14;12(38):6115-23
references.pmid: 17036381
references.citation: Am J Gastroenterol. 2003 Dec;98(12):2784-8
references.pmid: 14687833
references.citation: Gastroenterology. 1997 Jan;112(1):29-32
references.pmid: 8978339
references.citation: Am J Gastroenterol. 2003 Aug;98(8):1682-7
references.pmid: 12907319
references.citation: Inflamm Bowel Dis. 2007 Apr;13(4):367-71
references.pmid: 17206695
references.citation: J Am Med Inform Assoc. 2001 Nov-Dec;8(6):610-5
references.pmid: 11687567
references.citation: Gut. 2005 Nov;54(11):1573-8
references.pmid: 15994215
references.citation: Aliment Pharmacol Ther. 2000 Feb;14(2):145-53
references.pmid: 10651654
references.citation: Am J Gastroenterol. 2005 Jun;100(6):1345-53
references.pmid: 15929768
references.citation: Inflamm Bowel Dis. 2008 Feb;14(2):265-74
references.pmid: 17932965
references.citation: J Lab Clin Med. 2001 Sep;138(3):164-76
references.pmid: 11528369
references.citation: Inflamm Bowel Dis. 2008 Oct;14(10):1341-7
references.pmid: 18452197
references.citation: World J Gastroenterol. 2005 Jan 21;11(3):309-14
references.pmid: 15637733
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1262-7
references.pmid: 14652292
references.citation: Gastroenterol Clin North Am. 2006 Sep;35(3):675-712
references.pmid: 16952746
references.citation: N Engl J Med. 1990 Nov 1;323(18):1228-33
references.pmid: 2215606
references.citation: Gut. 2001 Apr;48(4):526-35
references.pmid: 11247898
references.citation: Gastroenterology. 2001 May;120(6):1356-62
references.pmid: 11313305
references.citation: Lancet. 2007 May 12;369(9573):1641-57
references.pmid: 17499606
references.citation: Clin Gastroenterol Hepatol. 2006 Nov;4(11):1346-50
references.pmid: 17059900
references.citation: Am J Gastroenterol. 2004 Jul;99(7):1371-85
references.pmid: 15233681
references.citation: Cancer. 2001 Feb 15;91(4):854-62
references.pmid: 11241255
references.citation: Eur J Gastroenterol Hepatol. 1996 Dec;8(12):1179-83
references.pmid: 8980937
references.citation: Int J Colorectal Dis. 2003 Sep;18(5):392-400
references.pmid: 12904996